- Oops!Something went wrong.Please try again later.
CORAL GABLES, FL / ACCESSWIRE / March 6, 2019 / The ascendancy of the biotech stock market to where it is today has only been made possible by the fact that biotech companies continue to formulate and manufacture top-of-the-line technologies for the purpose of the betterment of the human experience. It is inherently embedded in the framework of the biotech industry that companies should seek to improve life's technologies, and over the course of the past few years, we've witnessed companies in the industry rise to the occasion. If companies in the biotech sector continue to invent innovative medical technologies with a patient-centric focus, this could lead to significant investor attention in the near future. Premier Health Group (OTC:PHGRF) (CSE:PHGI), ImmunoGen Inc (IMGN), Tenax Therapeutics Inc (NASDAQ:TENX) and 22nd Century Group Inc (NYSE American: XXII) are four biotech companies focused on investing in the future of humanity.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company which is leading the healthcare industry in developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies to create a patient-centric healthcare framework. Where other companies have seemingly run out of steam, Premier continues to demonstrate its dedication to its patients, and to the future of healthcare.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) today announced that the Company is working with NexTech AR Solutions to explore bringing augmented reality technologies to its patient-centric healthcare app. Premier Health will be working with NexTech to develop educational tools for healthcare professionals and patients alike - some of which will be created and commercialized content for third parties. Utilizing AR as a learning tool in training healthcare professionals creates a highly engaging and immersive educational experience which aids in retention and how well complex concepts can be grasped.
In addition to their collaborative efforts, the companies will investigate possible AR treatment delivery options. For example, in relation to physiotherapy, digital demonstrations can be mapped directly onto the movements patients perform as part of their recovery.
Following the announcement, Dr. Essam Hamza, CEO of Premier Health Group (OTC:PHGRF) (CSE:PHGI), stated, "at Premier Health we pride ourselves in being at the forefront of changes in healthcare, so we are thrilled to be a part of the future of healthcare by enabling state of the art technological advancements to our patient-centric telemedicine app. AR has the potential to revolutionize both the access to data and the delivery of healthcare. The technology will help doctors and patients alike - doctors will have access to the latest and most relevant information about their patients while patients can use AR for self-education and improving the quality of treatment they receive."
ImmunoGen Inc (IMGN), a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced earlier this week that its Phase 3 FORWARD I trial evaluating the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in either the entire study population or in the pre-specified subset of patients with high FRα expression.
Following the announcement, Anna Berkenblit, Senior Vice President and Chief Medical Officer of ImmunoGen, said, "based upon the efficacy signals we observed in the high FRα subset with PFS, confirmed overall response rate and overall survival, we are conducting additional analyses to further evaluate the potential benefit of mirvetuximab soravtansine for FRα-positive platinum-resistant ovarian cancer."
Tenax Therapeutics Inc (TENX) a specialty pharmaceutical company focused on identifying and developing drugs that address diseases with a highly unmet medical need, announced in February that the Company's leadership team would present and conduct one-on-one meetings at the 2019 BIO CEO & Investor Conference in New York, NY.
As shareholders await an update from the meetings held at the conference, the Company saw impressive gains in the market on Wednesday, with its shares up 21.42%, trading at $1.52 per share late in the morning.
22nd Century Group Inc (XXII), a plant biotechnology company focused on tobacco harm reduction and low nicotine tobacco, announced just ahead of the new year that the Company had submitted a Modified Risk Tobacco Product application with the U.S. Food and Drug Administration for the Company's Very Low Nicotine Content cigarettes. 22nd Century's proposed VLNTM cigarettes, the subject of the MRTP application, are made with the Company's proprietary VLNTM tobacco and, as a result, contain very low levels of nicotine.
Per the Company's proposal, 22nd Century's proposed VLNTM cigarettes are the same as the lowest nicotine content style of the Company's SPECTRUM® research cigarettes. 22nd Century's SPECTRUM® research cigarettes were developed in collaboration with the FDA and other U.S. federal government agencies to provide independent scientists with the products necessary to investigate the public health benefits of reduced-nicotine content cigarettes.
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), MIDAM VENTURES, LLC and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 CASH for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to May 1, 2019. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
View source version on accesswire.com: